Edesa Biotech, Inc.

Fiscal 2016 total revenue increased by $0.51 million to $1.27 million from $0.76 million a year earlier. Product sales rose by $0.68 million to $1.24 million, compared with $0.56 million in fiscal 2015, while contract services revenue fell by $0.16 million. Total expenses increased to $6.18 million from $5.1 million, and the loss from operations widened to $4.91 million from $4.34 million. Net loss was $5.03 million, or $0.57 per basic share, versus a net loss of $2.84 million, or $0.36 per basic share, in fiscal 2015. Working capital was $11.48 million, with $11.41 million in cash, cash equivalents and short-term investments. For fiscal 2017, management estimated expenditures of approximately $6 million and said current working capital is sufficient for at least the next 12 months.

Frank Oakes framed 2016 as a year of substantial progress across market expansion, balance sheet strengthening, and manufacturing readiness. He emphasized that KLH demand is being driven by multiple clinical-stage immunotherapy programs and pointed to Neovacs, OBI Pharma, and Alzheimer’s-related programs as examples of the field’s momentum. His tone was upbeat and confident, repeatedly describing Stellar’s position as strategically strong and saying he is as excited about the company’s opportunities as he has been since its founding.

Kathi Niffenegger focused on the year’s financial progression and capital support for growth. She cited the $6.75 million equity financing completed in the fourth quarter, which helped lift year-end working capital to $11.48 million, including $11.41 million in cash, cash equivalents and short-term investments. She broke out the main cost drivers: cost of sales and contract services rose to $0.82 million, R&D increased to $1.73 million due to aquaculture and manufacturing development in the U.S. and Mexico, and G&A rose modestly to $3.32 million, partly from NASDAQ-related business development and investor relations costs. She also said the company may seek additional debt or equity if needed to accelerate programs.

Analysts focused heavily on how much KLH is needed for Phase 2 and Phase 3 studies, especially for customers like OBI Pharma and Neovacs. Management explained that usage is highly variable, but generally moves from tens of grams in early work to hundreds of grams in Phase 2 and potentially kilogram quantities for full commercial launches; they added that development work and manufacturing validation can consume more KLH than patient dosing alone. Questions also covered whether Alzheimer’s enthusiasm had weakened after failures in a different modality, and Frank Oakes said he did not see dampening interest because KLH conjugate vaccines use a different active-immunotherapy approach. Management also said California has enough capability for a launch, but Mexico is being pursued for geographic redundancy and long-term strategic flexibility.